CUMBERLAND PHARMACEUTICALS INC
CPIX · XNASCIK 1087294fmd_03G8128G9S7VPJ9ZZS7VNCBCE4Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Jun 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 33 | 26 | 29 | 34 | 37 | 36 | 42 | 40 | 38 | 45 |
| Cost of revenue | 6 | 5 | 6 | 7 | 9 | 9 | 9 | 6 | 7 | 7 |
| Gross profit | 27 | 21 | 23 | 27 | 29 | 27 | 33 | 33 | 31 | 38 |
| Realized investment gains (losses) | – | – | – | – | – | – | – | – | 0 | (0) |
| Research and development | 3 | 4 | 8 | 7 | 6 | 6 | 7 | 6 | 5 | 6 |
| Selling, general and administrative | 23 | 23 | 24 | 25 | 25 | 25 | 27 | 29 | 28 | 31 |
| Operating income | (1) | (9) | (11) | (9) | (6) | (8) | (6) | (10) | (6) | (3) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Interest and investment income | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | (1) | (9) | (11) | (9) | (7) | (6) | (6) | (6) | (6) | (3) |
| Income tax expense | (0) | 4 | 0 | (0) | 0 | 0 | 0 | 0 | (0) | 0 |
| Net income from continuing operations | (1) | (13) | (11) | (9) | (7) | (6) | (6) | (6) | (6) | (3) |
| Net income | (1) | (8) | (7) | (4) | (3) | (4) | (6) | (6) | (6) | (3) |